Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Previous participation in qualifying PsA study involving tofacitinib
Subjects who have completed at least 24 months of treatment with tofacitinib in the extension study
Subjects on a stable oral dose of methotrexate (maximum dose 20 mg per week)
You may not be if
Time from End of Study visit of qualifying study is \>3 months.
Pregnant female, breastfeeding female or female of childbearing potential unwilling or unable to use highly effective birth control for duration of study and one ovulatory cycle thereafter.
Subjects who are receiving methotrexate by a route other than oral
Clareo Health | Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
